NASDAQ:RGEN - Nasdaq - US7599161095 - Common Stock - Currency: USD
145.23
+3.83 (+2.71%)
The current stock price of RGEN is 145.23 USD. In the past month the price increased by 4.16%. In the past year, price decreased by -12.82%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 19.48 | 161.06B | ||
DHR | DANAHER CORP | 26.38 | 140.59B | ||
A | AGILENT TECHNOLOGIES INC | 20.15 | 30.51B | ||
IQV | IQVIA HOLDINGS INC | 13.53 | 26.57B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 26.12 | 22.40B | ||
WAT | WATERS CORP | 28.7 | 20.27B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.72 | 15.22B | ||
ILMN | ILLUMINA INC | 31.68 | 12.28B | ||
ICLR | ICON PLC | 10.42 | 12.05B | ||
RVTY | REVVITY INC | 19.41 | 11.43B | ||
AVTR | AVANTOR INC | 15.5 | 10.56B | ||
QGEN | QIAGEN N.V. | 19.48 | 9.31B |
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
REPLIGEN CORP
Building 1, Suite 100, 41 Seyon Street
Waltham MASSACHUSETTS 02453 US
CEO: Tony J. Hunt
Employees: 1783
Company Website: https://www.repligen.com/
Investor Relations: https://www.repligen.com/company/Investors/investors-overview
Phone: 17814499560
The current stock price of RGEN is 145.23 USD. The price increased by 2.71% in the last trading session.
The exchange symbol of REPLIGEN CORP is RGEN and it is listed on the Nasdaq exchange.
RGEN stock is listed on the Nasdaq exchange.
25 analysts have analysed RGEN and the average price target is 193.09 USD. This implies a price increase of 32.96% is expected in the next year compared to the current price of 145.23. Check the REPLIGEN CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
REPLIGEN CORP (RGEN) has a market capitalization of 8.16B USD. This makes RGEN a Mid Cap stock.
REPLIGEN CORP (RGEN) currently has 1783 employees.
REPLIGEN CORP (RGEN) has a resistance level at 145.24. Check the full technical report for a detailed analysis of RGEN support and resistance levels.
The Revenue of REPLIGEN CORP (RGEN) is expected to grow by 10.14% in the next year. Check the estimates tab for more information on the RGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RGEN does not pay a dividend.
REPLIGEN CORP (RGEN) will report earnings on 2025-04-29, before the market open.
The PE ratio for REPLIGEN CORP (RGEN) is 98.13. This is based on the reported non-GAAP earnings per share of 1.48 and the current share price of 145.23 USD. Check the full fundamental report for a full analysis of the valuation metrics for RGEN.
The outstanding short interest for REPLIGEN CORP (RGEN) is 6.56% of its float. Check the ownership tab for more information on the RGEN short interest.
ChartMill assigns a technical rating of 3 / 10 to RGEN. When comparing the yearly performance of all stocks, RGEN is a bad performer in the overall market: 70.25% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to RGEN. RGEN has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months RGEN reported a non-GAAP Earnings per Share(EPS) of 1.48. The EPS decreased by -14.45% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -0.53% | ||
ROE | -0.75% | ||
Debt/Equity | 0.26 |
ChartMill assigns a Buy % Consensus number of 78% to RGEN. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of 17.62% and a revenue growth 10.14% for RGEN